Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15087918 | 0.82 | MEN1 (0.38) | CYP1A2CYP3A4MEN1KMT2ACYP2C9 | |
| SCHEMBL90167 | 0.81 | SLC6A4 (0.38) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL18752369 | 0.78 | POLB (0.47) | SLC6A2SLC6A4SLC6A3CYP3A4ALDH1A1 | |
| SCHEMBL7869509 | 0.76 | PDE10A (0.37) | CYP1A2CYP3A4MEN1KMT2ACYP2C9 | |
| SCHEMBL89338 | 0.74 | REN (0.38) | REN | |
| SCHEMBL25600576 | 0.73 | L3MBTL1 (0.46) | CYP1A2CYP3A4MEN1KMT2ACYP2C9 | |
| SCHEMBL16455678 | 0.72 | AAK1 (0.39) | CYP1A2CYP3A4CYP2C19L3MBTL1KDM4E | |
| SCHEMBL10224229 | 0.70 | L3MBTL1 (0.65) | CYP1A2CYP3A4MEN1KMT2ACYP2C9 | |
| SCHEMBL90718 | 0.70 | POLB (0.37) | CYP1A2CYP3A4MEN1KMT2ACYP2C9 | |
| SCHEMBL27102695 | 0.69 | P2RX3 (0.47) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | SLC6A2 640/4885SLC6A4 895/4885SLC6A3 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.